The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.
Consecutive patients receiving New DES without a mixture of other DES
Study Type
OBSERVATIONAL
Enrollment
50,000
Korean centres
Multiple Locations, South Korea
RECRUITINGComposite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
Time frame: at 12 months post procedure
Death (all-cause and cardiac)
Time frame: at 12 months and annually up to 5 years
Myocardial infarction
Time frame: at 12 months and annually up to 5 years
Stent thrombosis
Time frame: at 12 months and annually up to 5 years
Target-lesion and target-vessel revascularization
Time frame: at 12 months and annually up to 5 years
Stroke
Time frame: at 12 months and annually up to 5 years
Procedural success
Time frame: at 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.